World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
118
Citations
51962
World Ranking
4056
National Ranking
2221

Zeev Estrov publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Zeev Estrov sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 996 publications — 94th percentile

94% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Zeev Estrov D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Zeev Estrov sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 118 D-Index — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Zeev Estrov is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily concentrates in the field of medicine, with a significant focus on hematology, genetics, molecular biology, immunology, and rheumatology. The subfield hematology accounts for the largest portion of their work.

The main topics covered in Estrov's research include:

  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Eosinophilic Disorders and Syndromes
  • Acute Lymphoblastic Leukemia research
  • Lymphoma Diagnosis and Treatment

Estrov has contributed to 225 medical publications, with hematology featuring prominently through 84 publications. Genetics and molecular biology fields also mark significant research activity. Their frequent publication venues include:

  • Blood (41 publications)
  • Clinical Lymphoma Myeloma & Leukemia (15 publications)
  • Leukemia (7 publications)
  • Cancer (7 publications)
  • American Journal of Hematology (5 publications)

Recent peer-reviewed papers involving or related to their work cover topics related to leukemias and antifungal prophylaxis, such as:

  • 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial (2020, The Lancet Haematology)
  • Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia (2021, JAMA Oncology)
  • Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study (2020, Clinical Infectious Diseases)
  • A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia (2020, Leukemia)
  • A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome (2021, Haematologica)

They frequently collaborate with other researchers, including:

  • Hagop M. Kantarjian
  • Naveen Pemmaraju
  • Srđan Verstovšek
  • Prithviraj Bose
  • Tapan M. Kadia

Best Publications

  • The biology of chronic myeloid leukemia

    Stefan Faderl;Moshe Talpaz;Zeev Estrov;Susan O'Brien

  • Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

    Srdan Verstovsek;Hagop Kantarjian;Ruben A. Mesa;Animesh D. Pardanani

  • Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

    Marina Konopleva;Rooha Contractor;Twee Tsao;Ismael Samudio

  • Adult stem cells for tissue repair - a new therapeutic concept?

    Martin Körbling;Zeev Estrov

  • Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells.

    Martin Körbling;Ruth L. Katz;Abha Khanna;Arnout C. Ruifrok

  • Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

    Alvaro Aguayo;Hagop M Kantarjian;Taghi Manshouri;Cristi Gidel

  • Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

    Hagop Kantarjian;Yasuhiro Oki;Guillermo Garcia-Manero;Xuelin Huang

  • Chronic Myelogenous Leukemia: Biology and Therapy

    Stefan Faderl;Moshe Talpaz;Zeev Estrov;Hagop M. Kantarjian

  • Chronic myelogenous leukemia: a concise update

    H. M. Kantarjian;A. Deisseroth;R. Kurzrock;Z. Estrov

  • Transdifferentiation of Human Peripheral Blood CD34+-Enriched Cell Population Into Cardiomyocytes, Endothelial Cells, and Smooth Muscle Cells In Vivo

    Edward T.H. Yeh;Sui Zhang;Henry D. Wu;Martin Körbling

  • Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

    Guillermo Garcia-Manero;Hagop M. Kantarjian;Blanca Sanchez-Gonzalez;Hui Yang

  • Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

    Andres O. Soriano;Hui Yang;Stefan Faderl;Zeev Estrov

  • Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

    Alessandra Ferrajoli;Bang-Ning Lee;Ellen J. Schlette;Susan M. O'Brien

  • Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.

    Alvaro Aguayo;Elihu Estey;Elihu Estey;Hagop M Kantarjian;Hagop M Kantarjian;Taghi Mansouri;Taghi Mansouri

  • Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells.

    Michael Sun;Zeev Estrov;Yuan Ji;Kevin R. Coombes

  • Ibrutinib and venetoclax for first-line treatment of CLL

    Nitin Jain;Michael Keating;Philip Thompson;Alessandra Ferrajoli

  • Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

    Antonina V. Kurtova;Kumudha Balakrishnan;Rong Chen;Wei Ding

  • Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

    Alfonso Quintás-Cardama;Hagop Kantarjian;Taghi Manshouri;Rajyalakshmi Luthra

  • Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

    Farhad Ravandi;Jorge E Cortes;Daniel Jones;Stefan H Faderl

  • Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia.

    Stefan Faderl;Hagop M. Kantarjian;Moshe Talpaz;Zeev Estrov

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center
Alessandra Ferrajoli
Alessandra Ferrajoli The University of Texas MD Anderson Cancer Center
William G. Wierda
William G. Wierda The University of Texas MD Anderson Cancer Center
Gautam Borthakur
Gautam Borthakur The University of Texas MD Anderson Cancer Center
Elias Jabbour
Elias Jabbour The University of Texas MD Anderson Cancer Center
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering alternative or related pathways to studying Medicine in the USA? Many students interested in healthcare careers look at nursing degrees, which offer flexible entry options and a variety of roles. Online education has expanded these opportunities, allowing students to balance study and work, or switch fields more easily.

For those seeking advanced qualifications, online nursing doctoral programs provide a path to leadership and research roles. If you're already an RN, exploring the average cost of rn to bsn programs can help you plan for the next step in your career.

Non-nurses looking to enter the profession quickly can consider an online direct entry msn, designed for those with a bachelor’s degree in another field. Additionally, some institutions offer direct admit nursing programs, making the process more accessible for new students.

Exploring these online degrees and career pathways can provide a flexible, cost-effective, and rewarding way to join the healthcare sector in the USA.

Best Scientists Citing Zeev Estrov

Trending Scientists

Recently Published Articles